• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性髓性白血病患者标准与低强度预处理方案的病例匹配比较。

Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients.

机构信息

Stem Cell Transplantation Unit, Department of Hematology, Faculty of Medicine, Ankara University, Cebeci Campus, 06590 Ankara, Turkey.

出版信息

Ann Hematol. 2012 Apr;91(4):577-86. doi: 10.1007/s00277-011-1349-2. Epub 2011 Oct 5.

DOI:10.1007/s00277-011-1349-2
PMID:21971669
Abstract

This retrospective case-matched study evaluated the efficacy of reduced intensity conditioning (RIC) regimen on early and late allogeneic transplant outcome in chronic myeloid leukemia (CML) patients. Twenty-eight patients conditioned with RIC regimen were matched to 56 patients who received a myeloablative conditioning (MAC) regimen. The main criteria for case matching among our CML allotransplant cohort were the Gratwohl scoring system. The median score was 2 (1-4) in each group. The pretransplant disease status was first chronic phase (CP1, n = 20), CP2 (n = 2), and advanced phase (n = 6) in RIC, and CP1 (n = 46), CP2 (n = 3), and advanced phase (n = 7) in MAC. The duration of neutropenia and thrombocytopenia was shorter in RIC than MAC. The grade and duration of mucositis were less in RIC. The need for total parenteral nutrition (21% vs. 77%, p < 0.0001) and febrile neutropenic episodes (50% vs. 95%, p < 0.0001) were observed less frequently in RIC compared with MAC-given patients. Acute or chronic graft versus host diseases (GvHD) were not affected by the intensity of conditioning regimen. The incidence of transplant-related mortality was higher in MAC (7% vs. 14%, p = 0.01). Although more relapse/progression was observed in the RIC group, the probability of 5- and 10-year leukemia-free- and overall survival were similar regardless of conditioning regimen intensity (p > 0.05). In early first CP, the pair of female donor-male recipient and the development of chronic GvHD prolonged both leukemia-free survival and overall survival in multivariate analysis. According to our single-center matched-pair analysis, the use of RIC regimens in patients with low-risk CML results with toxicities less, responses later, and relapses more frequent than the MAC regimens.

摘要

这项回顾性病例匹配研究评估了在慢性髓系白血病 (CML) 患者中,降低强度的预处理(RIC)方案对早期和晚期同种异体移植结果的疗效。28 例接受 RIC 方案预处理的患者与 56 例接受清髓性预处理(MAC)方案的患者进行了匹配。我们的 CML 异基因移植队列中病例匹配的主要标准是 Gratwohl 评分系统。每组的中位数评分为 2(1-4)。RIC 组患者的预处理前疾病状态为慢性期 1 期(CP1,n=20)、CP2(n=2)和进展期(n=6),MAC 组患者的预处理前疾病状态为 CP1(n=46)、CP2(n=3)和进展期(n=7)。RIC 组中性粒细胞减少和血小板减少的持续时间短于 MAC 组。RIC 组的粘膜炎程度较轻,持续时间较短。RIC 组总肠外营养(21% vs. 77%,p<0.0001)和发热性中性粒细胞减少症(50% vs. 95%,p<0.0001)的发生率低于 MAC 组。急性或慢性移植物抗宿主病(GvHD)不受预处理方案强度的影响。MAC 组的移植相关死亡率较高(7% vs. 14%,p=0.01)。尽管 RIC 组观察到更多的复发/进展,但无论预处理方案强度如何,5 年和 10 年无白血病生存率和总生存率的概率相似(p>0.05)。在早期 CP1 中,女性供体-男性受者配对和慢性 GvHD 的发展,在多变量分析中延长了无白血病生存率和总生存率。根据我们的单中心匹配对分析,RIC 方案在低危 CML 患者中的应用导致毒性降低、反应延迟和复发更频繁,而 MAC 方案则相反。

相似文献

1
Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients.慢性髓性白血病患者标准与低强度预处理方案的病例匹配比较。
Ann Hematol. 2012 Apr;91(4):577-86. doi: 10.1007/s00277-011-1349-2. Epub 2011 Oct 5.
2
Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.慢性髓性白血病患者异基因干细胞移植的低强度预处理与更好的总生存率相关,但与清髓性预处理相比,无病生存率较低——捷克国家造血干细胞移植登记处的一项回顾性研究。
Neoplasma. 2007;54(5):443-6.
3
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.急性白血病患者 HLA 全相合同胞异基因造血干细胞移植中,减低剂量预处理方案与清髓性预处理方案的比较结果:单中心经验
Transfus Apher Sci. 2013 Dec;49(3):590-9. doi: 10.1016/j.transci.2013.07.030. Epub 2013 Aug 8.
4
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.高危急性白血病异基因造血干细胞移植中标准与替代清髓性预处理方案的比较
Haematologica. 2002 Jan;87(1):52-8.
5
Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.成人高危完全缓解期急性淋巴细胞白血病行减低强度预处理与清髓性预处理异基因造血干细胞移植的长期结果比较。
Am J Hematol. 2013 Aug;88(8):634-41. doi: 10.1002/ajh.23465. Epub 2013 May 30.
6
A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation.一项前瞻性随机毒性研究比较了接受异基因造血干细胞移植的髓系白血病患者的低强度和清髓性预处理方案。
J Intern Med. 2013 Aug;274(2):153-62. doi: 10.1111/joim.12056. Epub 2013 Mar 25.
7
Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.预处理方案强度对异基因移植后急性和慢性移植物抗宿主病特征的影响。
Br J Haematol. 2005 Aug;130(3):394-403. doi: 10.1111/j.1365-2141.2005.05614.x.
8
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.在患有骨髓增生异常综合征或继发性急性髓系白血病的患者中,基于氟达拉滨/白消安的减低强度预处理后进行异基因干细胞移植。
Ann Hematol. 2003 Jun;82(6):336-42. doi: 10.1007/s00277-003-0654-9. Epub 2003 May 1.
9
Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.血液系统恶性肿瘤患者异基因干细胞移植的传统与降低强度预处理方案
Eur J Haematol. 2005 Feb;74(2):144-51. doi: 10.1111/j.1600-0609.2004.00360.x.
10
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.预处理强度对T细胞充足的单倍体相合干细胞移植治疗急性白血病的影响:欧洲血液与骨髓移植协会急性白血病工作组的报告
J Hematol Oncol. 2016 Mar 15;9:25. doi: 10.1186/s13045-016-0248-3.

引用本文的文献

1
Transplantation in CML in the TKI era: who, when, and how?TKI 时代的 CML 移植:谁、何时以及如何?
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):114-122. doi: 10.1182/hematology.2022000329.
2
Optimization of nutrition support practices early after hematopoietic cell transplantation.造血细胞移植后早期营养支持措施的优化
Bone Marrow Transplant. 2021 Feb;56(2):314-326. doi: 10.1038/s41409-020-01078-9. Epub 2020 Oct 10.
3
Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
慢性髓性白血病的异基因移植及酪氨酸激酶抑制剂对生存的影响:一项准实验研究。
Turk J Haematol. 2017 Mar 1;34(1):16-26. doi: 10.4274/tjh.2015.0346. Epub 2016 Apr 18.
4
Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.新诊断的加速期或急变期老年慢性髓性白血病患者的管理
Drugs Aging. 2016 May;33(5):335-45. doi: 10.1007/s40266-016-0351-8.
5
Allogeneic transplantation for CML in the TKI era: striking the right balance.TKI 时代的 CML 异基因移植:取得恰当的平衡。
Nat Rev Clin Oncol. 2016 Feb;13(2):79-91. doi: 10.1038/nrclinonc.2015.193. Epub 2015 Nov 17.
6
Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.突破极限——异基因造血移植的非清髓性和减低强度预处理方案
Bone Marrow Transplant. 2015 Sep;50(9):1157-67. doi: 10.1038/bmt.2015.61. Epub 2015 May 18.
7
The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.21世纪干细胞移植在慢性粒细胞白血病治疗中的作用。
Blood. 2015 May 21;125(21):3230-5. doi: 10.1182/blood-2014-10-567784. Epub 2015 Apr 7.
8
Comment on "Nutritional status of patients submitted to transplantation of allogeneic hematopoietic stem cells: a retrospective study".关于“接受异基因造血干细胞移植患者的营养状况:一项回顾性研究”的评论
Rev Bras Hematol Hemoter. 2014 Nov-Dec;36(6):392-3. doi: 10.1016/j.bjhh.2014.09.008. Epub 2014 Oct 1.